Premium
Characterization of a Hollow Fiber Bioartificial Liver Device
Author(s) -
AbuAbsi Susan Fugett,
Seth Gargi,
Narayanan Ramanathan A.,
Groehler Kristine,
Lai Pamela,
Anderson Mary L.,
Sielaff Timothy,
Hu WeiShou
Publication year - 2005
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.2005.29070.x
Subject(s) - bioartificial liver device , characterization (materials science) , fiber , biomedical engineering , materials science , chemistry , medicine , nanotechnology , composite material , biochemistry , hepatocyte , in vitro
A three‐compartment bioartificial liver (BAL) has been developed for potential treatment of fulminant hepatic failure. It has been shown previously that viability and liver‐specific functions were maintained in laboratory‐scale bioreactors of such design. In this study, the performance of hepatocytes in a clinical‐scale bioartificial liver was verified by sustained specific production rates of albumin and urea, along with oxygen consumption rates for up to 56 h and liver‐specific gene expression for up to 72 h. In addition, transmission of porcine endogenous retrovirus and other type C retroviral particles across the hollow fibers was not detected under both normal and extreme operating fluxes. These results demonstrate that the clinical‐scale BAL performs at a level similar to the laboratory scale and that it offers a viral barrier against porcine retroviruses.